Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden
Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
BMJ Open Diabetes Res Care. 2024 Jul 16;12(4):e004256. doi: 10.1136/bmjdrc-2024-004256.
In this systematic review, we investigated the diagnostic accuracy of surrogate measures of insulin secretion based on fasting samples and the oral glucose tolerance test (OGTT). The first phase of insulin secretion was calculated using two gold standard methods; the hyperglycemic clamp (HGC) test and intravenous glucose tolerance test (IVGTT).
We conducted searches in the PubMed, Cochrane Central, and Web of Science databases, the last of which was conducted at the end of June 2021. Studies were included that measured first-phase insulin secretion in adults using both a gold-standard reference method (either HGC or IVGTT) and one or more surrogate measures from either fasting samples, OGTT or a meal-tolerance test. QUADAS-2, a revised tool for the quality assessment of diagnostic accuracy studies, was used for quality assessment. Random-effects meta-analyses were performed to examine the correlation between first-phase measured with gold standard and surrogate methods.
A total of 33 articles, encompassing 5362 individuals with normal glucose tolerance, pre-diabetes or type 2 diabetes, were included in our systematic review. Homeostatic model assessment (HOMA)-beta and Insulinogenic Index 30 (IGI(30)) were the surrogate measures validated in the largest number of studies (17 and 13, respectively). HOMA-beta's pooled correlation to the reference methods was 0.48 (95% CI 0.40 to 0.56) The pooled correlation of IGI to the reference methods was 0.61 (95% CI 0.54 to 0.68). The surrogate measures with the highest correlation to the reference methods were Kadowaki (0.67 (95% CI 0.61 to 0.73)) and Stumvoll's first-phase secretion (0.65 (95% CI 0.58 to 0.71)), both calculated from an OGTT.
Surrogate measures from the first 30 min of an OGTT capture the first phase of insulin secretion and are a good choice for epidemiological studies. HOMA-beta has a moderate correlation to the reference methods but is not a measure of the first phase specifically.
The meta-analysis was registered at PROSPERO (Id: CRD42020169064) before inclusion started.
在这项系统评价中,我们调查了基于空腹样本和口服葡萄糖耐量试验(OGTT)的胰岛素分泌替代指标的诊断准确性。使用两种金标准方法计算胰岛素分泌的第一阶段;高血糖钳夹(HGC)试验和静脉葡萄糖耐量试验(IVGTT)。
我们在 PubMed、Cochrane 中心和 Web of Science 数据库中进行了检索,其中 Web of Science 的检索截止到 2021 年 6 月底。研究包括使用金标准参考方法(HGC 或 IVGTT)和一种或多种来自空腹样本、OGTT 或餐耐量试验的替代指标测量成年人第一阶段胰岛素分泌的研究。QUADAS-2 是一种用于诊断准确性研究质量评估的修订工具,用于质量评估。进行随机效应荟萃分析以检查用金标准和替代方法测量的第一阶段之间的相关性。
我们的系统评价共纳入 33 篇文章,涵盖了 5362 名糖耐量正常、糖尿病前期或 2 型糖尿病患者。稳态模型评估(HOMA)-β和胰岛素生成指数 30(IGI(30))是经过最多研究验证的替代指标(分别为 17 项和 13 项)。HOMA-β 与参考方法的汇总相关性为 0.48(95%CI 0.40 至 0.56),IGI 与参考方法的汇总相关性为 0.61(95%CI 0.54 至 0.68)。与参考方法相关性最高的替代指标是 Kadowaki(0.67(95%CI 0.61 至 0.73))和 Stumvoll 的第一阶段分泌(0.65(95%CI 0.58 至 0.71)),均来自 OGTT。
OGTT 前 30 分钟的替代指标可捕获胰岛素分泌的第一阶段,是流行病学研究的不错选择。HOMA-β 与参考方法有中度相关性,但不是专门测量第一阶段的指标。
在纳入研究开始之前,该荟萃分析已在 PROSPERO(Id:CRD42020169064)上进行了注册。